MATTERS ARISING

Bone mineral density and bone turnover in spinal osteoarthrosis

The study by Peel and colleagues1 of bone mineral density and bone turnover in spinal osteoarthrosis confirmed the finding of our own2 and other recent studies3-4 that bone density in osteoarthrosis is increased not because of osteophytes, but as a result of low bone turnover, as demonstrated using d-pyrnidinolincinc crosslinks as markers for bone resorption.

In line with the latter findings of low bone turnover, our observations indicate that osteos at the iliac crest survive longer in patients with osteoarthrosis, diagnosed by hand radiography. We found a significantly greater degree of mineralisation, as shown by gradient density bone fractionation5 and back scatter electron microscopy6.

In addition, we have been able to show that the mechanism of this high bone density in osteoarthrosis is attributable not only to a low turnover, but also to a high content of growth factors (insulin-like growth factor 1 and 2, and transforming growth factor β).7

JAN DEQUEKER
Arthritis and Metabolic Bone Disease Research Unit KU Leuven, Wetgeldervld I B-3012 Heverlee Belgium

JEAN-MARIE MBUYI-MIABA
Cliniques Universitaires de Kinshasa
BP 123, Kinshasa XI
Zaire

Correspondence to: Dr Dequeker.


LETTERS TO THE EDITOR

Effect of isradipine on endothelin-1 plasma concentrations in patients with Raynaud’s phenomenon

Raynaud’s phenomenon is a common microcirculatory disorder the pathogenesis of which remains obscure.1 Significantly increased concentrations of plasma endothelin-1 (ET-1), suggesting a possible pathogenic role of this peptide, have been reported in a majority of patients with Raynaud’s phenomenon.2 Among different agents used to treat the condition, generally with disappointing results,3 calcium antagonists seem to be the most useful.4 We have investigated the effects of a new calcium antagonist (isradipine) on vasoactive epis odes and plasma concentrations of ET-1 in patients with primary (type I) and suspected secondary (type II) Raynaud’s phenomenon, using a double blind, placebo controlled, and randomised parallel group trial.

The study was approved by the local ethics committee. In accordance with Kallemberg et al,5 patients were classified as having type I Raynaud’s phenomenon in the absence of other clinicoserological manifestations, and type II when Raynaud’s phenomenon was associated with one or more symptoms of connective tissue disease not fulfilling the American Rheumatism Association criteria for a definite diagnosis. After giving their informed consent, 33 consecutive outpatients (table) with active Raynaud’s phenomenon (14 with type I; 19 with type II), diagnosed according to Allen and Brown,6 were recruited to the study during the winter. The mean duration of their Raynaud’s phenomenon was 6.7 (SD 5) years (range 2-19). Subjects with a history of cardiopulmonary, renal, hepatic, or metabolic disorders, traumatic factors, or those treated with anti-inflammatory drugs were excluded from the trial; patients receiving vasodilator treatment underwent a two week washout period. Initially, each patient underwent careful physical examination, chest radiography, electrocardiography, and routine blood chemistry investigations. In addition, auto-antibodies (antinuclear antibody) were sought and nailfold capillary microscopy was performed according to techniques described previously7-8 (table).

Clinicopedimological, serological, and capilaroscopic characteristics of 33 patients with Raynaud’s phenomenon (RP)

<table>
<thead>
<tr>
<th>Sex (M/F)</th>
<th>Age (yr)</th>
<th>Duration of RP (yr)</th>
<th>Associated clinical features (%)</th>
<th>Auto-antibodies (%)</th>
<th>Nailfold capillary microscopy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capillary tortuosity (%)</td>
<td>Capillary loss (%)</td>
<td>Enlarged capillaries (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Type I RP (n = 14) | 1/13 | 38 (15) | 6/7 (59) | 44* | 0 | 64 | 37 | 32|
| Type II RP (n = 19) | 2/17 | 50 (15) | 6/7 (39) | 90** | 85† | 84 | 37 | 32|

Values are number, or mean (SD), as relevant.

Subsequently, patients were allocated randomly to receive, at 08:00, isradipine 5 mg/day (18 patients; eight with type I Raynaud’s phenomenon) or placebo (15 patients; six with type I Raynaud’s phenomenon) for a three week period. Patients treated with placebo were comparable to those in the group treated with isradipine as regards baseline clinicoserological values. Each patient received an instruction booklet and a clinical diary for daily recording of episodes of Raynaud’s phenomenon, variations in blood pressure, and possible side effects.

Statistical analysis was carried out by means of Student’s t and Wilcoxon’s tests.

At the beginning and the end of the trial, the plasma concentration of ET-1 was measured using a radioimmunoassay kit (Endothelin 1-2 RIA, Biomedica Gesellschaft mbH, Wien, Austria; normal values: mean = 0-49 pg/ml (2SD 0-20)) with some modifications.9 Four of the 33 patients enrolled, one receiving isradipine and three receiving placebo, withdrew after a few days of treatment because of low compliance. In isradipine treated patients only, there was a significant reduction in the number of acute attacks from a mean of 2-6 (SD 1-8; SEM 0-4)/day to 1-5 (0-9, 0-2)/day (p < 0-005); in discomfort score (on a scale of 0-10) from 7-4 (2-0, 6) to 5-2 (2-0, 5) (p < 0-0005); and in hand disability score (scale of 0-3) from 1-8 (1-4, 0-3) to 1-3 (0-9, 2) (p < 0-05). This clinical improvement was mirrored by a significant reduction in plasma concentrations of ET-1 from 1-60 (0-94, 0-25) pg/ml to 1-12 (0-67, 0-18) pg/ml (p < 0-025) (figure) during isradipine treatment. Patients receiving placebo did not show significant variations in any clinical parameter or in ET-1 concentrations. In the isradipine treated group, no differences were demonstrated between patients with type I and type II Raynaud’s phenomenon. In addition, no significant variations in blood pressure were observed.

In conclusion, we believe that isradipine might be useful in the treatment of Raynaud’s phenomenon. Further investigations are needed to confirm that the observed effects can be reproduced in other patients.

Ann Rheum Dis: first published as 10.1136/ard.55.5.331-a on 1 May 1996. Downloaded from http://ard.bmj.com/ on November 3, 2023 by guest. Protected by copyright.